Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis.

Semin Arthritis Rheum

Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Senior Scientist, Krembil Research Institute, University of Toronto Toronto, Ontario, Canada; Psoriatic Arthritis Program, Center for Prognostic Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto Western Research Institute, University Health Network, 399 Bathurst Street 1E-410B, Toronto, Ontario M5T 2S8, Canada. Electronic address:

Published: April 2019

Aims: To evaluate disease activity of late onset psoriatic arthritis (LoPsA) patients at presentation, during follow-up, and after 5years of follow-up, compared to young onset PsA patients (YoPsA).

Methods: The study included patients with PsA followed prospectively within 2years from diagnosis. Patients were divided into two groups: (1) LoPsA - defined as disease onset ≥ 50 years, (2) YoPsA - defined as disease onset < 50 years. Descriptive statistics are provided and multivariable logistic regression models were developed to compare these groups.

Results: Five hundred and sixty-six patients were included at presentation. Regression analysis showed that the LoPsA group at presentation was characterized by: less males (OR 0.4, p = 0.001), less HLA-C*06 (OR 0.3, p = 0.005), longer psoriasis duration (OR 1.04, p = 0.0005), higher BMI (OR 1.1, p = 0.005) and higher modified Steinbrocker score (mSS) (OR 1.1, p = 0.005). Regression analysis adjusted for gender, BMI, psoriasis duration, HLA and treatments after 5years of follow-up revealed a trend toward higher adjusted mean active joint count (OR 7.98, p = 0.052) and higher mean mSS score (OR 13.39, p = 0.007) in the LoSpA group compared to the YoPsA group. During 5years of follow-up, the YoPsA patients were treated with more NSAIDs (96% vs. 88%, p = 0.04), while there were no significant differences in the DMARDs and biologic drugs.

Conclusion: The LoPsA patients at presentation are characterized by female predominance, higher BMI, more damage and less HLA-C*06. After 5years of follow-up the LoPsA patients have worse prognosis manifested by a trend toward higher disease activity burden and significantly more damage.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2018.08.005DOI Listing

Publication Analysis

Top Keywords

late onset
8
onset psoriatic
8
psoriatic arthritis
8
defined disease
8
arthritis longitudinal
4
longitudinal cohort
4
disease
4
cohort disease
4
disease presentation
4
presentation activity
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!